← back to the rulings
JU-008 Tennis · Russia 2016

Maria Sharapova — A Heart Drug, a Calendar She Didn’t Read, and Fifteen Months

tennisindividual2010s
Sport
Tennis
Titles Lost
None (2016 Australian Open result voided)
Substance
Meldonium
Status
Banned

Summary

Maria Sharapova, the five-time Grand Slam champion and for eleven straight years the world's highest-earning female athlete, was banned for doping in 2016 — not for a steroid or a transfusion, but for a Latvian heart drug she had been taking openly for a decade, which the World Anti-Doping Agency had added to its prohibited list on the first day of that year. She tested positive at the Australian Open in January; the International Tennis Federation banned her two years in June; and on appeal the Court of Arbitration for Sport cut the sanction to fifteen months in October 2016, holding that she had not cheated on purpose but had still failed to do the one thing required of her — check whether her medication was still legal.

The substance was meldonium, sold under the brand name Mildronate, manufactured in Latvia and prescribed across the former Soviet bloc. Sharapova said a family doctor had put her on it in 2006 for a cluster of complaints — frequent illness, irregular EKG readings, a family history of diabetes. WADA banned it effective January 1, 2016, on evidence that athletes were using it to aid endurance and recovery. Sharapova kept taking it, and on January 26, 2016, a sample at the Australian Open came back positive. She had, in the most literal sense, been doping with a drug she had declared to no one because she had stopped reading the list that now contained it.

What makes the case unusual is how little of it turned on chemistry and how much on paperwork. Nobody disputed what was in her system or why. The fight was entirely about fault — how careless an athlete has to be, and how clearly a federation has to warn, before a positive for a newly banned drug becomes two years rather than fifteen months. The CAS panel found fault on both sides, hers for not checking and the testers' for burying the change in a wall of email, and split the difference.

It cost her the back half of a season, a chunk of her ranking, and the immediate suspension of contracts with Nike, Porsche, and TAG Heuer. It did not cost her a Grand Slam title; the only result disqualified was her quarter-final at the 2016 Australian Open. The verdict on record is a ban, and a relatively short one, for the rarest kind of doping case: the athlete caught by a change of rules rather than a change of behaviour.

Timeline

2006
The prescription
A doctor puts Sharapova on Mildronate (meldonium) for, she later says, frequent flu, abnormal EKG results, and a family history of diabetes.
2006–2016
A decade on the drug
She takes meldonium regularly, including before matches, without it ever appearing on a banned list — it was legal the entire time.
September 2015
The watch list confirms a ban
Having sat on WADA's monitoring program, meldonium is confirmed for prohibition; notice circulates that it joins the banned list on January 1, 2016.
January 1, 2016
The rule changes
Meldonium becomes prohibited. Sharapova continues taking it, later saying she did not click through to the updated list.
January 26, 2016
The positive test
A urine sample at the Australian Open, where she reached the quarter-finals, returns positive for meldonium.
March 7, 2016
The press conference
Sharapova announces the failed test herself at a Los Angeles hotel, saying she had taken Mildronate for ten years and missed the rule change.
March 8, 2016
Sponsors retreat
Nike, Porsche, and TAG Heuer suspend or pause their relationships with her within roughly a day.
June 8, 2016
The ITF ruling
An independent tribunal finds an anti-doping violation, disqualifies her Australian Open result, and bans her two years, backdated to January 26, 2016.
June 9, 2016
The appeal
Sharapova appeals to the Court of Arbitration for Sport, arguing "No Significant Fault" — she did not take meldonium to enhance performance.
September 7–8, 2016
The hearing
The CAS panel hears the parties in New York.
October 4, 2016
The reduction
CAS cuts the ban to fifteen months from January 26, 2016, ruling she was not an intentional doper but bore some fault, and criticising the ITF's notification of the change.
April 26, 2017
The return
Her suspension ends; she returns to competition that week on a wild card in Stuttgart.

The Drug Nobody Hid

Meldonium is not an exotic designer compound. It is an off-the-shelf medication, developed in Latvia in the 1970s, prescribed across Russia and Eastern Europe for cardiac conditions and marketed for everything from angina to "physical and psycho-emotional overload" in otherwise healthy people. It alters how cells metabolise fatty acids — plausibly useful to a patient with restricted blood flow to the heart and, anti-doping authorities concluded, also to an athlete recovering between bouts of maximal effort. That dual use is exactly why it ended up banned.

Sharapova's account was that she had taken it since 2006 on a doctor's recommendation, for a set of genuine-sounding complaints, and had simply kept taking what she was given. The CAS panel did not find this story dishonest; it accepted that she was not trying to cheat. The trouble was that the drug had been a legal supplement for her entire career right up until the moment it wasn't, and that moment was a date she could have learned by reading an email or following a link. The very ordinariness of the substance — that she had never had to think about it — was what made the lapse possible.

There is a quiet lesson in how meldonium got banned at all. It had sat on WADA's monitoring program — a watch list — precisely because the agency was seeing it in athlete samples in numbers no cardiac-patient population could explain. When it moved from watched to prohibited in 2016, dozens of Eastern European athletes promptly tested positive; Sharapova was simply the famous face. The drug had been hiding in plain sight across a region's sport, legal until the calendar said otherwise.

The Calendar She Didn't Read

The case turned on a single failure of housekeeping. Athletes at the top of the game do not personally memorise the prohibited list; they pay people to do it, and Sharapova was as professionally staffed as anyone in tennis. Yet the notice that meldonium was now banned passed through her organisation without anyone acting on it. She conceded she had received the emails carrying the rule change and had not opened the link; her support team, by the panel's account, had not been delegated the task of vetting her medications. One of the wealthiest, most scrutinised athletes alive thus kept taking a now-banned drug into a Grand Slam, then handed over a sample that announced it.

When the ITF tribunal weighed this in June 2016, it landed on two years — the standard sanction for a non-intentional violation, reduced from the four available for deliberate doping. Sharapova appealed on the ground of "No Significant Fault or Negligence," the code's mechanism for cases where an athlete's carelessness is real but modest, and CAS agreed the label fit. The panel was emphatic that "under no circumstances" could she be considered an intentional doper, and that her case "was not about an athlete who cheated." But it also held that she bore meaningful fault: a professional has a personal, non-delegable duty to know what she puts in her body, and "I assigned it to my team" does not discharge it.

The panel turned some blame on the testers, too, finding that the ITF and WADA had done a poor job of flagging that meldonium — a drug most players knew, if at all, by the brand name Mildronate — was now prohibited. The fifteen-month figure was the arithmetic of shared blame: enough to mark a real violation, short enough to acknowledge that the system meant to warn her had also fumbled. She was free to return on April 26, 2017.

The Cost of a Short Ban

For an athlete whose value was as much commercial as athletic, the damage arrived faster than any tribunal. Within roughly a day of her March press conference, Nike — which had backed her since she was eleven — suspended its relationship, and Porsche and TAG Heuer followed. Sharapova had topped Forbes's list of highest-paid female athletes for over a decade, and the suspensions struck at the income that dwarfed her prize money. A doping headline, even a non-intentional one, is read by the market as a single word.

On court, the sanction was almost surgically narrow. Because the ban was backdated and she had played no tournament between the Australian Open and her suspension, the only result disqualified was that quarter-final; none of her five Grand Slam titles was touched. The doping case did not end her career so much as bracket its decline.

The Five Factors

01
Strict liability does not care about your intentions
An athlete is responsible for whatever is in her sample, full stop. Sharapova's sincerity was never in doubt and never the point; the rule exists precisely so that "I didn't mean to" cannot become a defence, only a discount. Anyone who outsources what enters their body keeps the liability.
02
A watch list is a warning that the rules will move
Meldonium sat on WADA's monitoring program because the agency was already seeing it in athletes with no cardiac need for it. A substance on the watch list is a substance on its way to being banned, and treating "still legal today" as "safe indefinitely" is a bet against a calendar that always wins.
03
Duty of care cannot be delegated away
Sharapova had a large, paid support team and still kept taking a banned drug, because the task of checking her medications had fallen into the gap between her and her staff. The code makes the duty personal on purpose; an obligation that can be assigned to someone else can be quietly dropped.
04
Notification is the regulator's half of the bargain
CAS reduced the ban partly because the ITF and WADA had buried a material change in routine email, under a generic name rather than the brand athletes knew. A prohibited list only works if those bound by it are genuinely told; sloppy communication is a fault the system has to own.
05
Reputation prices a doping headline at one word
Sponsors did not wait for a tribunal or a finding of intent; they read "failed drug test" and moved within a day. For the commercially valuable athlete, the financial verdict is delivered by the market long before the sporting one, and it does not distinguish between a cheat and a careless reader.

Aftermath

Sharapova served the fifteen months and returned in late April 2017 at Stuttgart on a wild card. The comeback was respectable rather than triumphant: she won titles again but never another Grand Slam, and in February 2020 she retired at thirty-two, the doping ban now a permanent line in an otherwise glittering record. Several sponsors had resumed their relationships by then, the market having concluded that a non-intentional, short-ban case was survivable.

The episode's wider mark was on procedure rather than chemistry. The meldonium wave of 2016 — Sharapova plus dozens of lesser-known athletes — forced WADA to issue guidance on treating low-concentration positives from a drug whose clearance time had been poorly understood when it was banned. The Sharapova award itself became a standard teaching text on the "No Significant Fault" doctrine: a clean illustration of how tribunals apportion blame between a careless athlete and a careless system, and of how a two-year default can become fifteen months when both sides own a share of the lapse.

Lessons

  1. Treat the prohibited list as a live document, not a fixed fact: re-check every medication and supplement whenever the calendar turns, because what was legal for a decade can become a violation overnight.
  2. Make medication review an explicit, owned job — assign it in writing to a named person and verify it was done; a duty that lives in the gap between athlete and staff is a duty no one performs.
  3. If a substance appears on a monitoring or watch list, stop using it now rather than waiting for the ban; the watch list exists because the regulator already suspects what you are doing with it.
  4. For regulators: communicate rule changes in the names athletes actually use and confirm receipt, because a tribunal will dock your case for burying a material change in routine email.
  5. For sponsors and athletes alike: assume the market will not distinguish intent from cheating, and that the financial penalty arrives before, and lasts longer than, the sporting one.

References